Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
for Astrocytoma, IDH-Mutant, Grade 3
Drug: Vorasidenib
75 locations incl. Duarte
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 12+
Code: NCT07215910·Phase 3·Recruiting